Compare Rockwell Automation (ROK) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs Sana Biotechnology Inc — how do they compare? Rockwell Automation trades at $425.63 (market cap $47.32B), while Sana Biotechnology Inc trades at $3.19 (market cap $947.48M). The key difference: Rockwell Automation is far larger — about 49.9× Sana Biotechnology Inc's market cap, and Rockwell Automation pays a 1.3% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ROK | SANA | |
|---|---|---|
Market Cap | $47.32B | $947.48M |
Sector | Industrials | Health |
52-Week High | $495.08 | $5.92 |
52-Week Low | $333.75 | $2.68 |
Enterprise Value | $50.45B | $860.73M |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $429.13, down 1.08% on the day, with a bearish technical signal and mixed sentiment. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.49 exceeding expectations, but faces declining profit margins from 14.1% in 2023 to 10.41% in 2025. Analyst consensus is a Buy with a $514 price target, though technical indicators show resistance near $434 and support at $427.
The stock offers upside based on analyst targets and robust cash flow, but risks include margin pressure, high valuation multiples, and macroeconomic sensitivity. Institutional interest remains positive with recent investments, but investors should weigh the bearish technical trend against fundamental strengths in industrial automation demand.
SANA Biotechnology trades at $3.45, down 10.39% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $244.17 million for 2025, with ROE at -152.87%. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data for type 1 diabetes treatment.
Analyst consensus is strongly bullish with 81.82% buy ratings, but high cash burn and negative earnings pose significant risks. Upside potential hinges on clinical success and future profitability, while downside risks include sustained losses and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
